Eli Lilly Aktie 947556 / US5324571083
669.25
CHF
6.62
CHF
1.00%
26.11.2024
BRX
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Eli Lilly Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | Eli Lilly | 0.78 | 4.52 | USD |
| 2022 | Eli Lilly | 1.07 | 3.92 | USD |
| 2021 | Eli Lilly | 1.23 | 3.40 | USD |
| 2020 | Eli Lilly | 1.75 | 2.96 | USD |
| 2019 | Eli Lilly | 1.96 | 2.58 | USD |
| 2018 | Eli Lilly | 1.94 | 2.25 | USD |
| 2017 | Eli Lilly | 2.46 | 2.08 | USD |
| 2016 | Eli Lilly | 2.77 | 2.04 | USD |
| 2015 | Eli Lilly | 2.37 | 2.00 | USD |
| 2014 | Eli Lilly | 2.84 | 1.96 | USD |
Gewinn je Aktie- Eli Lilly
| 5.8 23 | 6.9 22 | 6.1 21 | 6.8 20 | 8.9 19 | 3.1 18 | -0.2 17 |
Umsatz je Aktie- Eli Lilly
| 37.8 23 | 31.6 22 | 31.1 21 | 26.9 20 | 23.9 19 | 23.8 18 | 21.7 17 |
KGV- Eli Lilly
| 100 23 | 53.0 22 | 45.1 21 | 24.9 20 | 26.5 19 | 37.0 18 |
Eli Lilly: Die Aktie (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 5.80 | 6.90 | 6.12 | 6.79 | 8.89 | 3.13 | -0.19 |
| Gewinn je Aktie unverwässert | 5.82 | 6.93 | 6.15 | 6.82 | 4.98 | 3.14 | -0.19 |
| Gewinn je Aktie verwässert | 5.80 | 6.90 | 6.12 | 6.79 | 4.96 | 3.13 | -0.19 |
| Dividende pro Aktie | 4.52 | 3.92 | 3.40 | 2.96 | 2.58 | 2.25 | 2.08 |
| Gesamtdividendenausschüttung in Mio. | 4’069.30 | 3’535.80 | 3’086.80 | 2’687.10 | 2’409.80 | 2’311.80 | 2’192.10 |
Eli Lilly: Unternehmenskennzahlen (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 37.78 | 31.55 | 31.06 | 26.89 | 23.85 | 23.76 | 21.74 |
| KGV (Jahresendkurs, EPS unverwässert) | 100.48 | 53.00 | 45.12 | 24.87 | 26.52 | 36.97 | - |
| KGV (Jahresendkurs, EPS verwässert) | 100.48 | 53.00 | 45.12 | 24.87 | 26.52 | 36.97 | - |
| KGV (Jahresendkurs) | 100.48 | 53.00 | 45.12 | 24.87 | 26.52 | 36.97 | - |
| Dividendenrendite Jahresende in % | 0.78 | 1.07 | 1.23 | 1.75 | 1.96 | 1.94 | 2.46 |
| Eigenkapitalquote in % | 16.97 | 21.77 | 18.76 | 12.49 | 6.87 | 24.85 | 25.94 |
| Fremdkapitalquote in % | 83.03 | 78.23 | 81.24 | 87.51 | 93.13 | 75.15 | 74.06 |
Eli Lilly: GuV (in Mio. USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 34’124.10 | 28’541.40 | 28’318.40 | 24’539.80 | 22’319.50 | 24’555.70 | 22’871.30 |
| Umsatzveränderung in % | 19.56 | 0.79 | 15.40 | 9.95 | -9.11 | 7.36 | 7.77 |
| Bruttoergebnis vom Umsatz | 27’041.90 | 21’911.60 | 21’005.60 | 19’056.50 | 17’598.30 | 18’125.70 | 16’801.10 |
| Bruttoergebnisveränderung in % | 23.41 | 4.31 | 10.23 | 8.29 | -2.91 | 7.88 | 7.93 |
| Operatives Ergebnis | 10’325.40 | 8’280.40 | 7’548.10 | 6’849.60 | 5’789.50 | 6’186.80 | 4’931.20 |
| Veränderung Operatives Ergebnis in % | 24.70 | 9.70 | 10.20 | 18.31 | -6.42 | 25.46 | 27.38 |
| Ergebnis vor Steuern | 6’554.60 | 6’806.40 | 6’155.50 | 7’229.90 | 5’265.90 | 3’795.70 | 2’197.40 |
| Veränderung Ergebnis vor Steuern in % | -3.70 | 10.57 | -14.86 | 37.30 | 38.73 | 72.74 | -34.87 |
| Ergebnis nach Steuer | 5’240.40 | 6’244.80 | 5’581.70 | 6’193.70 | 4’637.90 | 3’232.00 | -204.10 |
| Veränderung Ergebnis nach Steuer in % | -16.08 | 11.88 | -9.88 | 33.55 | 43.50 | - | - |
Eli Lilly: Bilanz (in Mio. USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 53’143 | 38’714 | 39’651 | 40’808 | 36’587 | 32’999 | 33’313 |
| Langzeit Gesamtverbindlichk. pro Aktie | 27.23 | 22.71 | 25.79 | 29.61 | 25.91 | 19.97 | 17.07 |
| Eigenkapital | 10’864 | 10’775 | 9’155 | 5’825 | 2’699 | 10’909 | 11’668 |
| Veränderung Eigenkapital in % | 1.15 | 18.61 | 59.16 | 116.41 | -73.48 | -15.21 | -17.24 |
| Bilanzsumme | 64’006 | 49’490 | 48’806 | 46’633 | 39’286 | 43’908 | 44’981 |
| Veränderung Bilanzsumme in % | 29.33 | 1.40 | 4.66 | 18.70 | -10.53 | -2.38 | 15.91 |
Eli Lilly: Sonstige Angaben (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 5.82 | 6.93 | 6.15 | 6.82 | 4.98 | 3.14 | -0.19 |
| Veränderung Gewinn je Aktie (unverwässert) in % | -15.94 | 12.53 | -9.81 | 36.99 | 58.64 | - | -107.34 |
| Gewinn je Aktie (verwässert) | 5.80 | 6.90 | 6.12 | 6.79 | 4.96 | 3.13 | -0.19 |
| Veränderung Gewinn je Aktie (verwässert) in % | -15.96 | 12.75 | -9.80 | 36.94 | 58.36 | - | -107.36 |
| Anzahl Mitarbeiter | 43’000 | 39’000 | 35’000 | 35’000 | 33’625 | 38’680 | 40’655 |
| Veränderung Anzahl Mitarbeiter in % | 10.26 | 11.43 | 0.00 | 4.09 | -13.07 | -4.86 | -3.14 |
Eli Lilly Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Eli Lilly | Quartalszahlen | 30.01.2025 |
| Eli Lilly | Quartalszahlen | 24.04.2025 |
| Eli Lilly | Quartalszahlen | 05.08.2025 |
| Eli Lilly | Quartalszahlen | 04.11.2025 |
Eli Lilly vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 30.10.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 08.08.2024 |
| Hauptversammlung | Annual General Meeting | 06.05.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 30.04.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 06.02.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 02.11.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 08.08.2023 |
| Hauptversammlung | Annual General Meeting | 01.05.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 27.04.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 02.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 01.11.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 04.08.2022 |
| Hauptversammlung | Annual General Meeting | 02.05.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 28.04.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 03.02.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 89.61 |
| Lilly Endowment, Inc. | 10.21 |
| Lilly Endowment, Inc. | 10.21 |
| The Vanguard Group, Inc. | 7.54 |
| Vanguard Group, Inc. (Subfiler) | 7.39 |
| PNC Financial Services Group, Inc. (13F Subfiler) | 5.41 |
| PNC Bank, NA (Investment Management) | 5.39 |
| State Street Corp. | 3.57 |
| Vanguard Total Stock Market ETF | 2.84 |
| Fidelity Management & Research Co. LLC | 2.53 |
| BlackRock Fund Advisors | 2.46 |
| Vanguard 500 Index Fund | 2.20 |
| Capital Research & Management Co. (World Investors) | 2.14 |
| T Rowe Price Associates, Inc. (13F Subfiler) | 2.09 |
| BlackRock Institutional Trust Co. NA | 1.87 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 40’655 | 38’680 | 33’625 | 35’000 | 35’000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.56 | 0.63 | 0.66 | 0.70 | 0.81 |
Bilanz (in Mio. USD) - Aktiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 19’202 | 20’550 | 13’710 | 17’462 | 18’452 |
| Summe Anlagevermögen | 25’779 | 23’359 | 25’577 | 29’171 | 30’354 |
| Summe Aktiva | 44’981 | 43’908 | 39’286 | 46’633 | 48’806 |
Bilanz (in Mio. USD) - Passiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 13’647 | 12’771 | 15’926 | 16’595 | 16’885 |
| Summe Fremdkapital | 33’313 | 32’999 | 36’587 | 40’808 | 39’651 |
| Summe Eigenkapital | 11’668 | 10’909 | 2’699 | 5’825 | 9’155 |
| Summe Passiva | 44’981 | 43’908 | 39’286 | 46’633 | 48’806 |
Adresse
| Lilly Corporate Center, 46285 Indianapolis | |
| Telefon | +1 (317) 276-2000 |
| URL | http://www.lilly.com |
Management
|
Alonzo Weems
Executive VP, Chief Ethics & Compliance Officer |
|
Anat Hakim
Secretary, Executive VP & General Counsel |
|
Andy Vicari
Senior Director & US Brand Leader-Insulins |
|
Anne E. White
Executive Vice President-Lilly Neuroscience |
|
Christian Nguyen
VP-Global Patient Outcomes & Real World Evidence |
|
Daniel M. Skovronsky
Chief Scientific Officer & Executive VP |
|
David A. Ricks
Chairman, President & Chief Executive Officer |
|
David Hyman
Chief Medical Officer |
|
Diogo Rau
Executive VP, Chief Information & Digital Officer |
|
Donald A. Zakrowski
Chief Accounting Officer & Vice President-Finance |
|
Edgardo Hernandez
President-Manufacturing Operations & Senior VP |
|
Eric Dozier
Executive VP-Human Resources & Diversity |
|
Gabrielle G. Greene-Sulzberger
Independent Director |
|
Ilya Yuffa
Senior VP & President-Lilly Bio Medicines |
|
Jacob S. van Naarden
Executive Vice President |
|
Jamere Jackson
Independent Director |
|
Jennifer Oleksiw
Global Chief Customer Officer & Vice President |
|
Joe Fletcher
Investor Relations Contact |
|
Jon Erik Fyrwald
Independent Director |
|
Juan Ricardo Luciano
Lead Independent Director |
|
Karen Walker
Independent Director |
|
Katherine Baicker
Independent Director |
|
Kim Macko
Head-Global Brand Development |
|
Kimberly H. Johnson
Independent Director |
|
Laura A. Lane
Vice President |
|
Lucas E. Montarce
Chief Financial Officer & Executive Vice President |
|
Mark Genovese
Senior Vice President-Immunology Development |
|
Mary Lynne Hedley
Independent Director |
|
Melissa Seymour
Executive Vice President-Global Quality |
|
Nathaniel R. Miles
Vice President-Strategic Initiatives |
|
Patrik Jonsson
EVP, President-Lilly Diabetes & Obesity |
|
Ralph Alvarez
Independent Director |
|
Robert Conley
Development Leader-Neuroscience |
|
Robert J. Heine
Vice President-Medical Affairs |
|
Ruth Gimeno
Vice President |
|
Thomas Fuchs
Chief Artificial Intelligence Officer |
|
Travis Coy
VP, Head-Transactions & Business Development |
|
William G. Kaelin
Independent Director |